p.133 抽出テキスト

symptomatic patients with lower-extremity peripheral artery disease: a systematic review and meta-analysis. Vasc Med 2022;27:158–70. https://doi.org/10.1177/ 1358863x211034577 295. O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US preventive services task force. JAMA 2020;324:2076–94. https://doi.org/10. 1001/jama.2020.17108 296. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021;4: CD010216. https://doi.org/10.1002/14651858.CD010216.pub5 297. Krabbe B, Espinola-Klein C, Malyar N, Brodmann M, Mazzolai L, Belch JJF, et al. Health effects of e-cigarettes and their use for smoking cessation from a vascular perspective. Vasa 2023;52:81–5. https://doi.org/10.1024/0301-1526/a001056 298. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb 299. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt C-A, Bellmunt-Montoya S, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc Endovasc Surg 2023;65:627–89. https://doi.org/10.1016/j.ejvs.2023.03.042 300. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178 301. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021;398:1053–64. https://doi.org/10.1016/S0140- 6736(21)01921-8 302. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/s0140- 6736(15)01225-8 303. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673–82. https://doi.org/10.1001/jama.2016.7050 304. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021;385:1268–79. https:// doi.org/10.1056/NEJMoa2111437 305. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/ hjh.0000000000000378 306. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–16. https://doi.org/10.1056/NEJMoa1511939 307. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. N Engl J Med 2000;342:145–53. https://doi.org/10.1056/ nejm200001203420301 308. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:48–53. https://doi.org/10.1161/hypertensionaha.109.142240 309. Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, et al. Association of hypertension and arterial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease: the EUCLID trial. Circ Cardiovasc Qual Outcomes 2020;13:e006512. https://doi.org/10.1161/circoutcomes. 120.006512 310. Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J, Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials. PLoS One 2017;12: e0178713. https://doi.org/10.1371/journal.pone.0178713 311. Lu Y, Ballew SH, Tanaka H, Szklo M, Heiss G, Coresh J, et al. 2017 ACC/AHA blood pressure classification and incident peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol 2020;27:51–9. https://doi.org/10.1177/ 2047487319865378 312. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. https://doi.org/10.1056/NEJMoa0801317 313. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17–24. https://doi.org/10.1016/j.ehj.2003.10.033 314. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev 2013;9:CD005508. https://doi.org/10.1002/14651858. CD005508.pub3 315. Kray JE, Dombrovskiy VY, Vogel TR. Use of angiotensin-converting enzyme inhibitors and freedom from amputation after lower extremity revascularization. Vasc Health Risk Manag 2017;13:269–74. https://doi.org/10.2147/vhrm.S137698 316. Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP. Use of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up study. Vasc Endovascular Surg 2012; 46:515–23. https://doi.org/10.1177/1538574412455229 317. Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med 2015;20:237–44. https://doi.org/10.1177/1358863x15574321 318. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001;87:1284–6. https://doi.org/10.1016/s0002-9149(01) 01521-1 319. Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D. Beta-blocker treatment does not worsen critical limb ischemia in patients receiving endovascular therapy. J Atheroscler Thromb 2015;22:481–9. https://doi.org/10.5551/jat.27359 320. Carey RM, Wright JT, Jr, Taler SJ, Whelton PK. Guideline-driven management of hypertension: an evidence-based update. Circ Res 2021;128:827–46. https://doi.org/ 10.1161/circresaha.121.318083 321. Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol 2014;9:1199–206. https://doi.org/10.2215/cjn.11611113 322. Hackam DG, Duong-Hua ML, Mamdani M, Li Ping, Tobe SW, Spence JD, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008;156:549–55. https://doi.org/10.1016/j.ahj.2008.05.013 323. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006;114:26–31. https://doi.org/10.1161/circulationaha.105. 592733 324. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370: 13–22. https://doi.org/10.1056/NEJMoa1310753 325. Mayr NP, Hapfelmeier A, Martin K, Kurz A, van der Starre P, Babik B, et al. Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcomedagger. Br J Anaesth 2016; 116:90–9. https://doi.org/10.1093/bja/aev294 326. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø study. Am J Epidemiol 2001;154:236–44. https://doi.org/10.1093/aje/154.3.236 327. Vogel TR, Dombrovskiy VY, Galiñanes EL, Kruse RL. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 2013;6:694–700. https://doi.org/10.1161/circinterventions.113. 000274 328. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014;35:2864–72. https://doi.org/10. 1093/eurheartj/ehu080 329. Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020;120:866–75. https://doi.org/10.1055/ s-0040-1709711 330. Su Z, Guo J, Gu Y. Pharmacotherapy in clinical trials for abdominal aortic aneurysms: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28: 10760296221120423. https://doi.org/10.1177/10760296221120423 331. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489 332. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10. 1161/CIRCULATIONAHA.116.021314 333. Clavijo LC, Caro J, Choi J, Caro JA, Tun H, Rowe V, et al. The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med 2023;55:1–5. https://doi.org/10.1016/j.carrev.2023.04.020 334. Cholesterol Treatment Trialists Collaboration; Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14) 61368-4 Downloaded from academic.oup.com/eurheartj/article/45/36/3538/7738955 by guest on 07 October 2026